Mankind Pharma (MANKIND) Share Price Falls 2.12% in Early Trade
- September 30, 2026
- Posted by: Kunal Singla
- Category: News
Mankind Share Price is trading at Rs 2,304.95, down 2.12% from the previous close, with Mankind Pharma valued at Rs 96,243.64 Cr in a Large Cap frame. The move keeps Mankind Share Price in focus for investors tracking Mankind Share Price Today, Mankind Stock News and Mankind Share Price Fall along with the company’s healthcare positioning.For readers following Univest coverage, the key task now is to separate the day’s price action from the company’s financial profile, sector comparison and peer valuation backdrop. Mankind Share Price therefore matters not only for the decline itself, but also for how the stock sits versus healthcare benchmarks on profit quality and valuation ratios.
Mankind Share Price also matters because the company is a Large Cap pharmaceutical name, and even a modest percentage move can change how the market reads the stock’s short-term positioning. Univest tracks such moves alongside Mankind Share Price Live, Mankind Share Price Update and Mankind Stock Analysis so investors can place the fall in a broader context without assuming a cause that is not verified.
Mankind Pharma (MANKIND) Share Price Today: Price Action Analysis
| Metric | Value |
|---|---|
| Current Price | Rs 2,304.95 |
| Previous Close | Rs 2,354.8 |
| Today's Move | -Rs 49.85 (-2.12%) |
| Open | Rs 2,354.6 |
| High | Rs 2,355 |
| Low | Rs 2,301.4 |
| Market Capitalisation | Rs 96,243.64 crore |
| Market Cap Category | Large Cap |
Mankind Share Price opened at Rs 2,354.60, touched a high of Rs 2,355.00 and a low of Rs 2,301.40, and was last traded at Rs 2,304.95. The current price is Rs 49.85 below the previous close of Rs 2,354.80, which works out to a 2.12% decline. That puts Mankind Share Price in the centre of today’s stock performance discussion, especially because the move occurred within a tight intraday band rather than through a wide swing.
With a market capitalisation of Rs 96,243.64 Cr, Mankind Pharma remains a Large Cap stock, so the day’s decline is being viewed against a significant base. Mankind Share Price Today therefore shows a clear price fall, but the range also shows that the stock traded near its opening level before easing lower. For readers scanning Mankind Share Price Today, the factual takeaway is simple: the stock is weaker, the move is measurable, and the market cap keeps it firmly in the large-company bracket. The next layer is fundamentals, because Mankind Share Price is not moving in isolation from valuation and earnings metrics.
Why Mankind Pharma (MANKIND) May Be Moving Today
Mankind Pharma (MANKIND) Fundamental Analysis
| Metric | Value |
|---|---|
| Market Capitalisation | Rs 96,243.64 crore |
| P/E Ratio | 47.62x |
| P/B Ratio | 5.78x |
| ROE | 12.69% |
| ROCE | 13.24% |
| EPS | Rs 49.45 |
| Book Value Per Share | Rs 407.39 |
| Dividend Yield | 0.04% |
Mankind Pharma (MANKIND) fundamental metrics show P/E 47.62x, P/B 5.78x, ROE 12.69%, ROCE 13.24%. These ratios show where the company stands today and are not a call to buy or sell.
Mankind Pharma has a market capitalisation of Rs 96,243.64 crore and falls in the Large Cap category, which gives readers a sense of company size before judging valuation. On valuation, P/E at 47.62x, P/B at 5.78x should be read against the sector and peer benchmarks rather than as a standalone signal. Profitability is represented by ROE of 12.69% and ROCE of 13.24%, helping investors compare shareholder returns and capital efficiency. According to latest Univest data, additional metrics include EPS of Rs 49.45, book value per share of Rs 407.39, dividend yield of 0.04%, adding context to earnings, balance-sheet value and historical payout. Against the latest Univest same industry benchmark, these figures can be compared with benchmark median P/E of 31.08x, median ROE of 11.48%, median ROCE of 13.28%. Together they describe the fundamental backdrop without implying a buy or sell view.
Sector and Industry Context
| Metric | Value |
|---|---|
| Sector | Healthcare |
| Industry | Pharmaceuticals & Drugs |
| Benchmark Scope | same industry |
| Company P/E Ratio | 47.62x |
| Benchmark Median P/E | 31.08x |
| Benchmark Average P/E | 46.65x |
| Benchmark P/E Range | 3.33x to 640x |
| Company P/B Ratio | 5.78x |
| Benchmark Median P/B | 2.87x |
| Benchmark Average P/B | 4.23x |
| Company ROE | 12.69% |
| Benchmark Median ROE | 11.48% |
| Benchmark Average ROE | 10.27% |
| Company ROCE | 13.24% |
| Benchmark Median ROCE | 13.28% |
| Benchmark Average ROCE | 13.16% |
| Company Market Capitalisation | Rs 96,243.64 crore |
| Benchmark Median Market Cap | Rs 806.56 crore |
| Benchmark Average Market Cap | Rs 13,634.43 crore |
Mankind Pharma (MANKIND) operates in the Healthcare sector, within the Pharmaceuticals & Drugs industry.
Mankind Pharma (MANKIND) has a P/E ratio of 47.62x, which is above the benchmark median of 31.08x, a difference of +53.22%. A P/E difference of this kind is a reference point rather than a recommendation.
Mankind Pharma (MANKIND) has a ROE of 12.69%, which is above the benchmark median of 11.48%, a difference of +10.54%. Mankind Pharma (MANKIND) has a ROCE of 13.24%, which is below the benchmark median of 13.28%, a difference of -0.3%.
Track stocks among today's decliners through the Univest top decliners screener. The peer table below provides the company-level comparison.
Peer Comparison
| Company | Symbol | Market Cap (Cr) | P/E | P/B | ROE (%) | ROCE (%) |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries | SUNPHARMA | 4,19,619.69 | 34.92 | 4.88 | 14.85 | 19.11 |
| Divi's Laboratories | DIVISLAB | 2,39,714.15 | 82.05 | 13.59 | 16.19 | 21.51 |
| Torrent Pharmaceuticals | TORNTPHARM | 1,74,740.99 | 80.33 | 19.52 | 26.76 | 19.27 |
| Zydus Lifesciences | ZYDUSLIFE | 1,12,119.43 | 25.21 | 4.22 | 19.69 | 21.39 |
| Laurus Labs | LAURUSLABS | 1,10,007.57 | 99.82 | 19.35 | 18.31 | 18.2 |
Mankind Pharma (MANKIND) has a P/E ratio of 47.62x compared with the displayed peer median of 80.33x. This is a relative valuation comparison, not a buy or sell signal. Its ROE of 12.69% compares with a peer median of 18.31% across the companies shown in the table. ROCE stood at 13.24% versus the displayed peer median of 19.27%, providing a capital-efficiency comparison. Mankind Pharma (MANKIND) has a market capitalisation of Rs 96,243.64 crore. All 5 peers shown have a larger market capitalisation.
Why Investors Are Watching Mankind Pharma
- Mankind Share Price is down 2.12% today, so traders are watching whether the decline stays contained or extends further in the session.
- The current price of Rs 2,304.95 sits below the previous close of Rs 2,354.80, which keeps Mankind Share Price in active focus on Univest.
- Mankind Share Price carries a P/E of 47.62 and a P/B of 5.78, which makes valuation an important part of the discussion.
- ROE at 12.69% and ROCE at 13.24% give Mankind Share Price a return profile that investors can compare with healthcare peers.
- The stock belongs to the Healthcare sector and Pharmaceuticals & Drugs industry, so sector benchmark comparison remains relevant for Mankind Share Price.
About Mankind Pharma
Mankind Pharma operates in the Healthcare sector and the Pharmaceuticals & Drugs industry. The company is part of the Large Cap universe by market capitalisation, with a market value of Rs 96,243.64 Cr. Mankind Share Price therefore reflects a business that sits among major listed pharmaceutical names in India. The company works in a segment where valuation, earnings quality and return ratios often influence how investors compare one name with another. For readers following Mankind Stock News, the business context is straightforward: this is a large healthcare company whose stock is assessed against both sector peers and broader pharma benchmarks. Mankind Share Price today is only one part of that larger company profile.
Track Mankind Share Price on Univest
Use Mankind Pharma (MANKIND) live share-price page, Univest top decliners screener, Univest market blogs to review live stock data, top decliners and related market analysis.
Track Mankind Share Price on Univest for live updates, fundamental ratios, 52-week levels and market insights in one place. Univest also helps readers follow Mankind Share Price Today, Mankind Stock Analysis and Mankind Share Price Update alongside key company metrics. If you are reviewing Mankind Share Price after today’s decline, the same page keeps the price action, valuation and sector context together for quick reference.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Uniresearch Global Pvt. Ltd. (Research Analyst, SEBI Reg. No. INH000013776, a subsidiary of Univest Communication Technologies Private Limited).
Frequently Asked Questions
Why is Mankind Share Price falling today?
Ans. Mankind Share Price is down 2.12% at Rs 2,304.95 versus the previous close of Rs 2,354.80.
What is the current Mankind Share Price?
Ans. Mankind Share Price is trading at Rs 2,304.95. The stock moved between Rs 2,301.40 and Rs 2,355.00 during the day, keeping the decline contained within a relatively narrow intraday range.
What is Mankind Pharma’s market capitalisation?
Ans. Mankind Pharma has a market capitalisation of Rs 96,243.64 Cr and is categorised as a Large Cap stock. That size context is important when reading Mankind Share Price and its day-to-day movement.
How does Mankind Share Price compare on valuation?
Ans. Mankind Share Price has a P/E ratio of 47.62 and a P/B ratio of 5.78. Both metrics sit above the benchmark median for the pharmaceutical industry, which makes valuation part of the story.
What do ROE and ROCE show for Mankind Pharma?
Ans. ROE is 12.69% and ROCE is 13.24% for Mankind Pharma. Those return ratios are close to the industry benchmark, which gives Mankind Share Price a balanced operating context. The relevant peer median ROE is 11.48%.
What is the book value and EPS for Mankind Share Price?
Ans. EPS stands at Rs 49.45 and book value is Rs 407.39. These per-share figures help explain the earnings base and accounting net worth behind Mankind Share Price. The previous close was Rs 2,354.8.
How does Mankind Share Price compare with healthcare peers?
Ans. Mankind Share Price trades above Zydus Lifesciences and Sun Pharma on P/E, while Divi’s Laboratories and Torrent Pharmaceuticals carry higher valuation multiples. The peer set gives useful context for comparison.
Is Mankind Share Price linked to any reported corporate development?
Ans. A news item reported an investment of up to €45 million in the Netherlands subsidiary and a planned 70% stake purchase in Armed Cell Therapeutics for €48 million.
Should investors track Mankind Share Price on Univest?
Ans. Yes, investors tracking Mankind Share Price can use Univest for live price, valuation ratios, peer comparison and sector context. That helps place today’s decline alongside the company’s broader financial profile.
